Literature DB >> 12389870

A critical review of the toxicological effects of carrageenan and processed eucheuma seaweed on the gastrointestinal tract.

Samuel M Cohen1, Nobuyuki Ito.   

Abstract

Carrageenan is a high-molecular-weight, strongly anionic polymer derived from several species of red seaweed that is used for the textural stabilization of foods. Processed Eucheuma Seaweed (PES) is a form of carrageenan with a higher cellulose content. Food-grade carrageenan has a weight average molecular weight greater than 100,000 Da, with a low percentage of smaller fragments. Carrageenan is not degraded to any extent in the gastrointestinal tract and is not absorbed from it in species examined, such as rodents, dogs, and non-human primates. Systemically administered carrageenan has been reported to have a variety of effects, particularly on the immune system, but these are not pertinent to orally administered carrageenan. The substance poligeenan (formerly referred to as degraded carrageenan) is not a food additive. It exhibits toxicological properties at high doses that do not occur with the food additive carrageenan. In-long term bioassays, carrageenan has not been found to be carcinogenic, and there is no credible evidence supporting a carcinogenic effect or a tumor-promoting effect on the colon in rodents. Also, like many dietary fibers, there is significant cecal enlargement in rodents when it is administered at high doses, but this does not appear to be associated with any toxicological consequences to the rodent. Many toxicological studies on carrageenan have involved administration at doses in excess of today's standards for dietary feeding levels in bioassays, and they are orders of magnitude in excess of those to which humans are exposed. Previous reviews of carrageenan and PES by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives (JECFA) have recommended a group allowable daily intake (ADI) of "not specified". The lack of carcinogenic, genotoxic, or tumor-promoting activity with carrageenan strongly supports continuing such an ADI, and JECFA, during its most recent review in 2001, continued this recommendation. The various toxicological studies related to orally administered food-grade carrageenan are summarized along with a brief discussion of critical factors in intestinal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389870     DOI: 10.1080/20024091064282

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  17 in total

Review 1.  A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

Authors:  Chenere P Ramsey; Malú G Tansey
Journal:  Exp Neurol       Date:  2013-05-28       Impact factor: 5.330

2.  Iota-carrageenan is a potent inhibitor of influenza A virus infection.

Authors:  Andreas Leibbrandt; Christiane Meier; Marielle König-Schuster; Regina Weinmüllner; Donata Kalthoff; Bettina Pflugfelder; Philipp Graf; Britta Frank-Gehrke; Martin Beer; Tamas Fazekas; Hermann Unger; Eva Prieschl-Grassauer; Andreas Grassauer
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

3.  Non-clinical safety evaluation of intranasal iota-carrageenan.

Authors:  Alexandra Hebar; Christiane Koller; Jan-Marcus Seifert; Monika Chabicovsky; Angelika Bodenteich; Andreas Bernkop-Schnürch; Andreas Grassauer; Eva Prieschl-Grassauer
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

4.  Anticancer and cancer preventive properties of marine polysaccharides: some results and prospects.

Authors:  Sergey N Fedorov; Svetlana P Ermakova; Tatyana N Zvyagintseva; Valentin A Stonik
Journal:  Mar Drugs       Date:  2013-12-02       Impact factor: 5.118

5.  Synergistic effect of κ-carrageenan on oxazolone-induced inflammation in BALB/c mice.

Authors:  Wei Wu; Feng Wang; Xin Gao; Tingting Niu; Xiaojuan Zhu; Xiaojun Yan; Haimin Chen
Journal:  BMC Gastroenterol       Date:  2016-03-25       Impact factor: 3.067

6.  κ-Carrageenan Enhances Lipopolysaccharide-Induced Interleukin-8 Secretion by Stimulating the Bcl10-NF-κB Pathway in HT-29 Cells and Aggravates C. freundii-Induced Inflammation in Mice.

Authors:  Wei Wu; Zhanghe Zhen; Tingting Niu; Xiaojuan Zhu; Yuli Gao; Jiangyan Yan; Yu Chen; Xiaojun Yan; Haimin Chen
Journal:  Mediators Inflamm       Date:  2017-01-09       Impact factor: 4.711

7.  Degraded carrageenan causing colitis in rats induces TNF secretion and ICAM-1 upregulation in monocytes through NF-kappaB activation.

Authors:  Claudine Benard; Antonietta Cultrone; Catherine Michel; Carlos Rosales; Jean-Pierre Segain; Marc Lahaye; Jean-Paul Galmiche; Christine Cherbut; Hervé M Blottière
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

8.  The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.

Authors:  Martina Morokutti-Kurz; Marielle König-Schuster; Christiane Koller; Christine Graf; Philipp Graf; Norman Kirchoff; Benjamin Reutterer; Jan-Marcus Seifert; Hermann Unger; Andreas Grassauer; Eva Prieschl-Grassauer; Sabine Nakowitsch
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

9.  Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis.

Authors:  Christine Graf; Andreas Bernkop-Schnürch; Alena Egyed; Christiane Koller; Eva Prieschl-Grassauer; Martina Morokutti-Kurz
Journal:  Int J Gen Med       Date:  2018-07-04

10.  Inhibitory Effects of Carrageenans on Endotoxin-Induced Inflammation.

Authors:  Irina M Yermak; Aleksandra V Volod'ko; Eleonora I Khasina; Viktoriya N Davydova; Evgeniy A Chusovitin; Dmitry L Goroshko; Anna O Kravchenko; Tamara F Solov'eva; Victor V Maleev
Journal:  Mar Drugs       Date:  2020-05-10       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.